Flow cytometric analysis of Neuro-2a (Mouse neuroblastoma neuroblast, left) / RAW 264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage, right) labelling 4-1BBL antibody at 1/200 dilution (1 μg) / (red) compared with a Rat monoclonal IgG (black) Isotype Control. Goat Anti - Rat IgG Alexa Fluor® 488 was used as the secondary antibody. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Negative control: Neuro-2a
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | 4-1BBL (CD137L) |
| Synonyms | Tumor necrosis factor ligand superfamily member 9; 4-1BB ligand (4-1BBL); Cd137l; Cd157l; Ly63l; Tnfsf9 |
| Location | Membrane |
| Accession | P41274 |
| Clone Number | S-3760 |
| Antibody Type | Rat mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | RAW 264.7 |
| Purification | Protein G |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:200 | Ms |
Background
4-1BBL (CD137L, TNFSF9) is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) superfamily that serves as the cognate ligand for the 4-1BB (CD137) receptor, a costimulatory molecule expressed on activated T cells, natural killer (NK) cells, and dendritic cells (DCs). Primarily expressed on antigen-presenting cells (APCs) including mature DCs, B cells, macrophages, and endothelial cells, 4-1BBL engages with its receptor in a trimeric configuration to deliver potent costimulatory signals that promote T cell survival, proliferation, cytokine production (particularly IFN-γ), and enhanced cytotoxic activity, while also activating NK cells and DCs to amplify anti-tumor immune responses. This interaction plays a critical role in sustaining T cell immunity during chronic antigen exposure and has emerged as a promising therapeutic target in cancer immunotherapy, with agonistic antibodies targeting the 4-1BB/4-1BBL axis being developed to enhance T cell function in solid tumors and hematological malignancies, as well as being incorporated into chimeric antigen receptor (CAR) T cell designs to improve persistence and efficacy.
Picture
Picture
FC
